
Project Details
PRIME
Biparametric MRI or multiparametric MRI for prostate cancer diagnosis
Status:
Completed
Prospective, international, within-patient, non-inferiority trial that demonstrates that biparametric is non-inferior to multiparametric MRI in the diagnosis of clinically significant and insignificant prostate cancer.


International Collaboration
22
centres
12
countries
Published in JAMA,
2025
Altmetric
1477
Summary
Problem
Gap
Methodology
Key results
Impact
Top Recruting Centres
Sapienza University, Italy
50
patients recruited

Principal Investigator
Professor Valeria Panebianco
University of Udine, Santa Maria della Misericordia, Italy
48
patients recruited

Principal Investigator
Professor Rossano Girometti
Princess Margaret Cancer Centre, Canada
40
patients recruited

Principal Investigator
Professor Sangeet Ghai
Reina Sofia, Spain
40
patients recruited

Co-Principal Investigator
Dr Enrique Gomez-Gomez

Co-Principal Investigator
Dr Daniel Lopez-Ruiz
Martini Klinik, Germany
40
patients recruited

Principal Investigator
Prof Lars Budäus
University Hospital Düsseldorf, Germany
38
patients recruited

Co-Principal Investigator
Prof Jan Philipp Radtke

Co-Principal Investigator
Prof Lars Schimmöller
Awards
RSNA Trainee Research Prize in Genitourinary Imaging (2024)
RSM Urology Section Runner-Up in Professor Geoffrey D. Chisholm CBE Communication Prize (2025)

For patients and public
In centres with high-quality MRI and experienced radiologists, a shorter scan without contrast performs as well as the longer contrast scan. Overall, bpMRI can shorten appointments and remove the need for a cannula, helping more people get the scans they need.
No difference in finding important or unimportant cancers
No increase in the number of men advised to have a biopsy
No differences in false positives / specificity
Only minor differences in treatment decisions
Wish to be involved in contributing to research ideas, please get in touch



